Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding, thromboembolic, vascular complications, Re-admission and increased in the length of hospital stay during the 30-day post-radiofrequency catheter ablation(RFCA) period among patients who interrupt NOAc 24hours before ablation and patients who stop NOAC in the morning of the procedure.

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: novel oral anticoagulant for 30 days
* Drug: novel oral anticoagulant for 24 hour


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who consent with study Patients with Atrial fibrillation (20-80 years old) patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation Patients possible to NOAC Exclusion Criteria: Patients who do not agree with study inclusion eGRF < 30ml/min Impossible to NOAC Structural cardiac disease Major hemorrhagic complication CHA2DS2-VASc score > 5 Patients who have experienced Ischemic cerebellar infarction more than 2times

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: The group of keep medication NOAC<br>The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation | Drug: novel oral anticoagulant for 30 days<br>* novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.<br>|
| Active Comparator: The group of stop medication NOAC 1 day<br>The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation | Drug: novel oral anticoagulant for 24 hour<br>* novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of major bleeding complications | Bleeding complication is assessed by physical examination or laboratory measurement | during 30 days post-AF ablation. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of thromboembolism | thromboembolism is diagnosed by both clinical situations and image studies combined. | during 30 days post-AF ablation. | 
| incidence of minor bleeding |  | during 30 days post-AF ablation. | 
| Re-admission rate related procedure |  | during 30 days post-AF ablation. | 
| length of hospital stay |  | during 30 days post-AF ablation. | 
| incidence of vascular complications | vascular complication is diagnosed by both clinical situations and image studies combined. | during 30 days post-AF ablation. |